- Select a blog category
This week we're delighted to feature a guest blog written by Fiona Maini and Sarah Chan who both work in Deloitte's Risk Advisory practice. The focus is on the new clinical trials regulation and what it means for Life Science companies.
The increase in the value of mergers and acquisitions (M&A) in the life sciences and healthcare (LSHC) sector during 2014 is continuing in 2015 (see Figure 1). In 2014, life sciences companies announced some $441 billion worth of acquisitions, the highest figure for well over a decade. By the middle of July 2015, $379 billion worth of transactions have already been announced, which means that 2015 could be a record-breaking year for M&A in the sector.
For this week’s ‘Thoughts from the Centre’ we’re delighted to share an article written by a US colleague: Terri Cooper – PhD, Principal, Federal Health Sector Leader, Deloitte Consulting LLP. Terri’s ‘My Take’ discusses the challenges surrounding precision medicine and how recent trends are helping to unlock its potential.
Jeremy Hunt’s recent comments on what he called a “Monday to Friday” working culture within the NHS sparked fury amongst NHS staff and set off a mass response through social media sites with doctors being singled out as needing to “get real” about seven-day working. This was the backdrop that overshadowed the release of the long-awaited Rose Report[i] whose key messages were to enable better engagement of the clinical workforce with management of the NHS. This week’s guest blog is by a colleague who has spent most of her career in the NHS and explores some of the rhetoric and reality behind these events.
Since the turn of the 21st Century government has been supporting its citizens through on-line services and electronic data capture. More recently, the public sector has begun adopting digital processes and operating models in response to unpreceded cost pressures and rising public expectation. While previous Thoughts from the Centre blogs have focused on the use of technology in the health and social care sector, this week we consider Deloitte’s research into the progress made by the public sector as a whole in embracing the digital revolution, to identify the broader systemic issues and solutions which the NHS and social care might learn from.
Over the past few weeks, national and international media coverage has been rife with speculation about whether Greece will retain the Euro. At the time of posting this blog, Eurozone leaders have agreed to the conditions for Greece to seek a third bailout and the Greek government agreed to accept the bailout conditions - but several European Union (EU) members, including Germany, must ratify the deal in their parliaments before it can proceed.[i] Whatever happens over the next few weeks there is still some way to go and uncertainty about Greece’s financial future. This week’s blog does not attempt to predict the outcome but examines a key issue challenging the pharma industry, the impact of the current economic turmoil and continued uncertainty on pharmaceutical pricing.
On July 8th 2015 the Chancellor of the Exchequer confirmed his Government’s commitment to provide additional funding for the NHS however there was little if any mention of social care funding, suggesting that no new money will be forthcoming for social care unless it’s found from the healthcare budget. If you then factor in the budget announcement of at least four more years of pay restraint for NHS staff, which will inevitably affect recruitment and retention and likely increase the need for more expensive temporary staff, the financial challenges facing the NHS remain enormous. This week’s blog looks at some of the immediate implications of the 2015 budget in relation to health and social care in 2015-16.
In our report Connected Health: How digital technology is transforming health and social care we highlighted the increasing pervasiveness of health apps and an urgent need to help patients and clinicians understand the efficacy and effectiveness of individual apps. We noted that, depending on definition, there are more than 100,000 health apps available to download from the various app stores; with the sheer number and variety of apps confusing clinicians and patients alike. Research in October 2013 that focused on 43,000 wellness, diet and exercise apps found that only 23,682 had a legitimate health function and most had limited and simple functionality. Indeed around 50 per cent achieved fewer than 500 downloads. So far there are about 450 health apps that have been tried and recommended by patients’ organisations featured www.myhealthapps.net and even fewer approved by the NHS Choices Health Apps Library.i
Our report in 2012, ‘Primary Care ‘Today and Tomorrow: improving general practice by working differently’, highlighted the significant challenges facing general practice and the need for general practice to work differently to cope effectively with the increasing demands it was facing.i Some three years later the findings still resonate.
The number of people being diagnosed with and surviving cancer is increasing every year. As of 2015, an estimated 2.5 million people are living with cancer in the UK, an increase of 400,000 people in just five years.
This week the NHS held its annual NHS Confederation Conference in Liverpool, providing an opportunity for the NHS to set out its stall for the next five years. With clear endorsement from the new Conservative Government for the NHS Five Year Forward View (FYFV), all eyes were on Simon Stevens, Chief Executive of NHS England, as he set out his stall.